Herceptin Research Today is a free monthly online journal that collates and summarizes the latest research about Herceptin, including details on side-effects, breast cancer, treatment, therapy.

Volume 1 (2004), Issue 2 (December)

1. Dual HER 1-2 targeting of hormone-refractory prostate cancer by ZD1839 and trastuzumab.
   Eur J Cancer, 40(18): 2837-44. [Abstract] [Full-text]
2. Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy.
   J Am Coll Cardiol, 44(11): 2231-8. [Abstract] [Full-text]
3. Targeting of HER2 antigen for the treatment of disseminated peritoneal disease.
   Clin Cancer Res, 10(23): 7834-41. [Abstract] [Full-text]
4. Early changes in protein expression detected by mass spectrometry predict tumor response to molecular therapeutics.
   Cancer Res, 64(24): 9093-100. [Abstract] [Full-text]
5. SRL172 (killed Mycobacterium vaccae) may augment the efficacy of trastuzumab in metastatic breast cancer patients.
   Med Hypotheses, 64(2): 248-51. [Abstract] [Full-text]
6. Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer.
   Clin Cancer Res, 10(24): 8185-94. [Abstract] [Full-text]

© 2004-2008 Herceptin Research Today. All Rights Reserved.